研究等業績 - その他 - 成田 伸太郎
-
LAPARO-ENDOSCOPIC SINGLE-SITE (LESS) PLUS ONE TROCAR LAPAROSCOPIC DONOR NEPHRECTOMY UTILIZING GELPORT: AN INITIAL CLINICAL EXPERIENCE
Takamitsu Inoue, Norihiko Tsuchiya, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Mitsuru Saito, Shintaro Narita, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF ENDOUROLOGY ( MARY ANN LIEBERT INC ) 25 A84 - A85 2011年11月
研究発表要旨（国際会議）
-
A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.
Kazuyuki Numakura, Norihiko Tsuchiya, Takeshi Yuasa, Mitsuru Saito, Takashi Obara, Hiroshi Tsuruta, Shintaro Narita, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi
International journal of clinical oncology 16 ( 5 ) 577 - 80 2011年10月
We report a case of Xp11.2 translocation renal cell carcinoma (RCC) whose lung metastases were effectively treated with sunitinib. A 43-year-old woman presenting with upper abdominal pain was diagnosed with a left renal tumor. Laparoscopic left radical nephrectomy was performed. Histopathological examination of the surgical specimen revealed a clear-cell carcinoma of the left kidney. Two years later, multiple lung metastases were detected and the patient was treated daily with 50 mg sunitinib. A computed tomography scan performed after 2 cycles of sunitinib treatment revealed partial regression of these metastases. The partial regression has been maintained for >3 years. In retrospective evaluation of the primary RCC, tumor cells showed strong nuclear staining for transcription factor E3 (TFE3) protein and TFE3 split-fluorescence in-situ hybridization revealed translocation involving the TFE3 gene. These findings strongly support diagnosis of Xp11.2 translocation RCC.
-
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Mitsuru Saito, Takashi Obara, Kazuyuki Numakura, Shinya Maita, Shigeru Satoh, Norihiko Tsuchiya, Tomonori Habuchi
International journal of clinical oncology 16 ( 5 ) 533 - 8 2011年10月
BACKGROUND: To evaluate the efficacy and toxicity of a combination chemotherapy consisting of gemcitabine, carboplatin, and docetaxel (GCD) in patients with advanced urothelial carcinoma (UC) as a phase II trial. MATERIALS AND METHODS: Patients with metastatic or locally advanced unresectable UC were eligible for this trial. All enrolled patients were considered to be "unfit" for cisplatin-based chemotherapy, or to have methotrexate, vinblastine, doxorubicin, cisplatin (MVAC)-refractory UC. The chemotherapy regimen consisted of gemcitabine 1000 mg/m(2) on days 1 and 8, and carboplatin (with a target area under the curve of 5) and docetaxel 70 mg/m(2) on day 1; this was repeated every 21 days. RESULTS: Thirty-five patients were enrolled, with a median age of 68 years. A total of 89 cycles were administered (median, 2 cycles). Major toxicities were Grade 3/4 neutropenia in 28 (80.0%) patients and Grade 3/4 thrombocytopenia in 18 (51.5%). An objective response rate (ORR) was 11 of 21 patients (52.4%), including a complete response in 1 (4.8%). The median overall survival (OS) was 13.1 months (1-year survival rate, 60%) and the median progression-free survival (PFS) was 5.0 months. Among 16 patients who had previously received MVAC, the ORR, the median PFS, the median OS and 1-year survival rate was 56.3%, 5.0 months, 12.6 months and 54%, respectively. CONCLUSIONS: GCD chemotherapy is active and well tolerated as a first- or second-line therapy for patients with advanced UC. Response rate, duration and survival did not differ between those with and without a history of MVAC treatment.
-
Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility.
Naoko Kawata, Norihiko Tsuchiya, Yohei Horikawa, Takamitsu Inoue, Hiroshi Tsuruta, Shinya Maita, Shigeru Satoh, Yoko Mitobe, Shintaro Narita, Tomonori Habuchi
International journal of cancer 129 ( 8 ) 1872 - 80 2011年10月
Abnormal survivin expression has been reported to be involved in many types of cancer. A single-nucleotide polymorphism (SNP), C-31G, located in the promoter region of survivin reportedly may alter the mRNA level, while the significance of the nonsynonymous SNP A9194G in exon 4 has not yet been clarified. Here, the association between the two survivin SNPs and bladder cancer susceptibility and progression was investigated in 235 patients with bladder cancer and 346 healthy controls. Regarding the C-31G SNP, subjects with the CC genotype had a significantly higher risk of bladder cancer compared to those with the GG + CG genotype [odds ratio (OR) = 1.85, p = 0.001]. Regarding the A9194G SNP, the presence of the G allele was associated with a significantly reduced risk with a gene dosage effect (OR = 0.69, p = 0.002). Using the C-A haplotype as a reference, the G-G haplotype was associated with a significantly lower risk (OR = 0.11, p = 0.00006), indicating the cooperative effect of the two SNPs. Immunohistological evaluation of surgical specimens showed that cancer cells of the C-31G CC genotype had significantly higher nuclear survivin expression than those of the C-31G GG + CG genotype. With reverse transcriptase-polymerase chain reaction analysis, a significantly higher survivin mRNA expression level was observed in surgical specimens with an increase in the number of the C-31G C allele (p = 0.016). These results indicate that the two SNPs have a significant and cooperative influence on bladder cancer susceptibility.
-
癌関連遺伝子SNPパネルを用いた転移性前立腺癌の予後予測(Prediction of survival in metastatic prostate cancer patients by SNP panel of cancer-associated genes)
土谷 順彦, 松井 茂之, 成田 伸太郎, 神波 大己, 三塚 浩二, 畠山 真吾, 堀川 洋平, 井上 高光, 斎藤 誠一, 大山 力, 荒井 陽一, 小川 修, 羽渕 友則
日本癌学会総会記事 ( 日本癌学会 ) 70回 455 - 456 2011年09月
-
Correlations between pretransplant dialysis duration, bladder capacity, and prevalence of vesicoureteral reflux to the graft.
Takamitsu Inoue, Shigeru Satoh, Mitsuru Saito, Kazuyuki Numakura, Hiroshi Tsuruta, Takashi Obara, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi
Transplantation 92 ( 3 ) 311 - 5 2011年08月
BACKGROUND: Urinary bladder capacity is reduced in patients undergoing long-term dialysis, which may increase the risk of vesicoureteral reflux (VUR) to a transplanted kidney. This study investigated the correlations between dialysis duration, pretransplant and posttransplant bladder capacity, and prevalence of VUR to the graft. METHODS: Voiding cystography was performed in 101 adult renal transplant recipients without neurogenic disorders immediately before and 1 year after transplantation to evaluate bladder capacity and VUR. Nonstented extravesical antireflux ureteroneocystostomy was performed in all patients. RESULTS: The median dialysis duration and pretransplant bladder capacity were 32 months (range 1-426 months) and 120 mL (range 15-450 mL), and 21 patients (20.8%) underwent dialysis for more than 120 months, and 30 patients (29.7%) had a pretransplant bladder capacity of less than 80 mL. Dialysis duration was correlated with pretransplant bladder capacity (R=0.466, P<0.001). Bladder capacity expanded more than 6-fold from pretransplantation to posttransplantation, and all recipients had a bladder capacity greater than 150 mL at 1 year posttransplantation. Thirty patients had VUR to the graft. Dialysis duration longer than 60 months (P=0.021) and pretransplant bladder capacity of less than 130 mL (P=0.024) were associated with VUR. VUR was associated with lower graft function. CONCLUSIONS: Although bladder capacity decreased because of long-term dialysis, it exceeded 150 mL at 1 year posttransplantation. A small bladder can be used in renal transplantation, but it may increase the risk of VUR.
-
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
Zsofia Kote-Jarai, Ali Amin Al Olama, Graham G Giles, Gianluca Severi, Johanna Schleutker, Maren Weischer, Daniele Campa, Elio Riboli, Tim Key, Henrik Gronberg, David J Hunter, Peter Kraft, Michael J Thun, Sue Ingles, Stephen Chanock, Demetrius Albanes, Richard B Hayes, David E Neal, Freddie C Hamdy, Jenny L Donovan, Paul Pharoah, Fredrick Schumacher, Brian E Henderson, Janet L Stanford, Elaine A Ostrander, Karina Dalsgaard Sorensen, Thilo Dörk, Gerald Andriole, Joanne L Dickinson, Cezary Cybulski, Jan Lubinski, Amanda Spurdle, Judith A Clements, Suzanne Chambers, Joanne Aitken, R A Frank Gardiner, Stephen N Thibodeau, Dan Schaid, Esther M John, Christiane Maier, Walther Vogel, Kathleen A Cooney, Jong Y Park, Lisa Cannon-Albright, Hermann Brenner, Tomonori Habuchi, Hong-Wei Zhang, Yong-Jie Lu, Radka Kaneva, Ken Muir, Sara Benlloch, Daniel A Leongamornlert, Edward J Saunders, Malgorzata Tymrakiewicz, Nadiya Mahmud, Michelle Guy, Lynne T O'Brien, Rosemary A Wilkinson, Amanda L Hall, Emma J Sawyer, Tokhir Dadaev, Jonathan Morrison, David P Dearnaley, Alan Horwich, Robert A Huddart, Vincent S Khoo, Christopher C Parker, Nicholas Van As, Christopher J Woodhouse, Alan Thompson, Tim Christmas, Chris Ogden, Colin S Cooper, Aritaya Lophatonanon, Melissa C Southey, John L Hopper, Dallas R English, Tiina Wahlfors, Teuvo L J Tammela, Peter Klarskov, Børge G Nordestgaard, M Andreas Røder, Anne Tybjærg-Hansen, Stig E Bojesen, Ruth Travis, Federico Canzian, Rudolf Kaaks, Fredrik Wiklund, Markus Aly, Sara Lindstrom, W Ryan Diver, Susan Gapstur, Mariana C Stern, Roman Corral, Jarmo Virtamo, Angela Cox, Christopher A Haiman, Loic Le Marchand, Liesel Fitzgerald, Suzanne Kolb, Erika M Kwon, Danielle M Karyadi, Torben Falck Orntoft, Michael Borre, Andreas Meyer, Jürgen Serth, Meredith Yeager, Sonja I Berndt, James R Marthick, Briony Patterson, Dominika Wokolorczyk, Jyotsna Batra, Felicity Lose, Shannon K McDonnell, Amit D Joshi, Ahva Shahabi, Antje E Rinckleb, Ana Ray, Thomas A Sellers, Hui-Yi Lin, Robert A Stephenson, James Farnham, Heiko Muller, Dietrich Rothenbacher, Norihiko Tsuchiya, Shintaro Narita, Guang-Wen Cao, Chavdar Slavov, Vanio Mitev, Douglas F Easton, Rosalind A Eeles
Nature genetics 43 ( 8 ) 785 - 91 2011年07月
Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. We conducted a multi-stage genome-wide association study for PrCa and previously reported the results of the first two stages, which identified 16 PrCa susceptibility loci. We report here the results of stage 3, in which we evaluated 1,536 SNPs in 4,574 individuals with prostate cancer (cases) and 4,164 controls. We followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. In addition to replicating previously reported loci, we identified seven new prostate cancer susceptibility loci on chromosomes 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (P = 4.0 × 10(-8) to P = 2.7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified.
-
A case of intratesticular endometrioid papillary cystadenocarcinoma.
Kazuyuki Numakura, Norihiko Tsuchiya, Hiroshi Tsuruta, Takashi Obara, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Shigeru Satoh, Hiroshi Nanjyo, Tomonori Habuchi
Japanese journal of clinical oncology 41 ( 5 ) 674 - 6 2011年05月
We report a case of intratesticular endometrioid papillary cystadenocarcinoma. A 73-year-old man was admitted for a painless right scrotal swelling. Ultrasonography and computed tomography revealed a large cystic mass in the right testis. Right scrotum puncture revealed xanthochromic fluid with negative cytology. Three months later, follow-up computed tomography showed enlargement of the cystic mass. Right high orchiectomy was performed because a testicular malignancy was suspected. The pathological diagnosis was endometrioid papillary cystadenocarcinoma, and the cells were strongly positive for the estrogen and progesterone receptors. Testicular neoplasms resembling common ovarian-type epithelial tumors are very rare. This is the first report of endometrioid papillary cystadenocarcinoma of the testis.
-
CLINICAL CHARACTERISTICS OF XP11.2 TRANSLOCATION RENAL CELL CARCINOMA IN ADULT JAPANESE PATIENTS
Kazuyuki Numakura, Norihiko Tsuchiya, Takeshi Yuasa, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Shingo Hatakeyama, Chikara Ohyama, Toru Inoue, Hiromitsu Mimata, Hideo Saito, Yoichi Arai, Toru Kanno, Tomomi Kamba, Osamu Ogawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E706 - E706 2011年04月
-
BASILIXIMAB INDUCTION THERAPY COMBINED WITH A LOWER TARGET TROUGH LEVEL OF TACROLIMUS AND LOW DOSE OF MYCOPHENOLATE MOFETIL DECREASED INTERSTITIAL FIBROSIS AT 1-YEAR POSTTRANSPLANTATION AND IMPROVED THE 5-YEAR GRAFT SURVIVAL
Shigeru Satoh, Kazuyuki Numakura, Mitsuru Saito, Yoshiko Miura, Takashi Obara, Hiroshi Tsuruta, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi, Hideaki Kagaya, Masatomo Miura
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E905 - E905 2011年04月
研究発表要旨（国際会議）
-
ELEVATED URINE LEVELS OF RANTES AND HIGH EXPRESSION LEVELS OF THE RANTES RECEPTOR (CCR5) IN BLADDER CANCER
Hiroshi Tsuruta, Yohei Horikawa, Shintaro Narita, Takamitsu Inoue, Takashi Obara, Kazuyuki Numakura, Shinya Maita, Shigeru Sato, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E496 - E496 2011年04月
研究発表要旨（国際会議）
-
EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN/CD147) IS ASSOCIATED WITH MALIGNANT PHENOTYPES OF HUMAN BLADDER CANCER
Kiyofumi Satoyoshi, Noriko Yamaguchi, Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E349 - E349 2011年04月
研究発表要旨（国際会議）
-
FACTORS ASSOCIATED WITH QUANTITATIVE INTERSTITIAL FIBROSIS AT 0-HOUR (DONOR) BIOPSY BY COMPUTERIZED IMAGE ANALYSIS IN LIVING DONORS
Yoshiko Miura, Shigeru Satoh, Mitsuru Saito, Kazuyuki Numakura, Hiroshi Tsuruta, Takashi Obara, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habichi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E903 - E903 2011年04月
研究発表要旨（国際会議）
-
IMPACT OF CLINICAL CHARACTERISTICS AND PRETRANSPLANT URINARY BLADDER CAPACITY ON URODYNAMICS ONE YEAR POSTTRANSPLANTATION IN 54 ADULT RECIPIENTS
Takashi Obara, Shigeru Satoh, Kazuyuki Numakura, Hiroshi Tsuruta, Shintaro Narita, Horikawa Yohei, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E830 - E830 2011年04月
研究発表要旨（国際会議）
-
POSTTRANSPLANT HYPERURICEMIA IN THE EARLY STAGE OF RENAL TRANSPLANT RECIPIENTS: INCIDENCE, CLINICAL CHARACTERISTICS, TACROLIMUS PARMACOKINETICS, AND RELATED GENOMIC POLYMORPHISMS
Kazuyuki Numakura, Shigeru Satoh, Norihiko Tsuchiya, Mitsuru Saito, Takamitsu Inoue, Takashi Obara, Hiroshi Tsuruta, Shintaro Narita, Yohei Horikawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E906 - E906 2011年04月
研究発表要旨（国際会議）
-
PREDICTION OF SURVIVAL IN METASTATIC PROSTATE CANCER PATIENTS BY SNP ARRAY ANALYSIS OF CANCER-ASSOCIATED GENES
Norihiko Tsuchiya, Shigeyuki Matsui, Shintaro Narita, Takamitsu Inoue, Kazuyuki Numakura, Yohei Horikawa, Shingo Hatakeyama, Chikara Ohyama, Youichi Arai, Seiichi Saito, Osamu Ogawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E917 - E917 2011年04月
研究発表要旨（国際会議）
-
PREOPERATIVE SERUM LEVELS OF INTERLEUKIN-6 AND INTERLEUKIN-12 PREDICT BIOCHEMICAL RECURRENCE IN PATIENTS WITH PROSTATE CANCER TREATED USING RADICAL PROSTATECTOMY
Shintaro Narita, Norihiko Tsuchiya, Shinya Maita, Takashi Obara, Kazuyuki Numakura, Hiroshi Tsuruta, Takamitsu Inoue, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E937 - E937 2011年04月
研究発表要旨（国際会議）
-
PROSTATE CANCER PROGRESSION UNDER HIGH-FAT DIET IS ENHANCED BY MCP-1/CCR2 SIGNALING
Mingguo Huang, Shintaro Narita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Takamitsu Inoue, Yohei Horikawa, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 185 ( 4 ) E115 - E115 2011年04月
研究発表要旨（国際会議）
-
A case of ureteral malignant lymphoma diagnosed by laparoscopic needle biopsy.
Kazuyuki Numakura, Norihiko Tsuchiya, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi
Japanese journal of clinical oncology 41 ( 3 ) 440 - 2 2011年03月
A pathological diagnosis of a lesion in the ureteral wall is often attended with a difficulty. We report a case of a 54-year-old man who presented a thickening of the ureteral wall and diffuse swelling of paraaortic lymph nodes diagnosed as a non-Hodgkin lymphoma by a laparoscopic needle biopsy. This is a safe and useful technique by which target tissues can be surely obtained.
-
Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus.
Yoshiko Miura, Shigeru Satoh, Mitsuru Saito, Kazuyuki Numakura, Takamitsu Inoue, Takashi Obara, Hiroshi Tsuruta, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Atsushi Komatsuda, Hideaki Kagaya, Masatomo Miura, Tomonori Habuchi
Transplantation 91 ( 1 ) 78 - 85 2011年01月
BACKGROUND: This study investigated the increase in interstitial fibrosis (IF) from 0 hr to 1 month and 1 year posttransplantation in biopsy sections and assessed the risk of developing IF in 118 living kidney recipients. METHODS: A quantitative analysis of IF was performed using computer-assisted imaging. The percent IF (%IF) in the cortical region at 0 hr was defined as the baseline, and the increases in %IF at 1 month and 1 year were calculated. Demographics, higher (regimen 1) and lower (regimen 2) target trough concentrations of tacrolimus, and the cytochrome P450 (CYP) 3A5 polymorphism were tested as risk factors. RESULTS: The mean %IF at 0 hr, 1 month, and 1 year was 10.3%+/-4.2%, 15.0%+/-5.8%, and 19.0%+/-7.7%, respectively. %IF increased 1.7- and 2.2-fold from 0 hr to 1 month and 1 year posttransplantation, respectively. At 1 year, the increase was higher in patients with the CYP3A5*3/*3 genotype (nonexpressers), those treated with regimen 1, and those with a lower estimated glomerular filtration rate and higher body mass index. In a multivariate analysis, CYP3A5 nonexpression correlated with the development of IF (odds ratio 2.63, P=0.018). Tacrolimus blood levels in the early stage posttransplantation were higher in nonexpressers than CYP3A5 expressers in both regimens 1 and 2, despite therapeutic drug monitoring. CONCLUSIONS: The higher concentrations of tacrolimus, especially in the nonexpressers treated with regimen 1, might influence the development of IF. This study suggested that a new regimen with lower and narrow target trough levels of tacrolimus or a dosing strategy based on the CYP3A5 genotype is needed to reduce the risk of developing IF.